Session

PP 05 IBD (Posters)

USTEKINUMAB TREATMENT IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A REAL-WORLD COMPARISON BETWEEN ITS EFFECTIVENESS AND SAFETY IN THIS TWO POPULATIONS
USTEKINUMAB TREATMENT IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A REAL-WORLD COMPARISON BETWEEN ITS EFFECTIVENESS AND SAFETY IN THIS TWO POPULATIONS

PP 05 IBD (Posters)  et al.

INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ENDOMETRIOSIS: CHARACTERIZATION AND 1-YEAR CLINICAL OUTCOME IN A PROSPECTIVE STUDY
INFLAMMATORY BOWEL DISEASE WITH CONCOMITANT ENDOMETRIOSIS: CHARACTERIZATION AND 1-YEAR CLINICAL OUTCOME IN A PROSPECTIVE STUDY

PP 05 IBD (Posters)  et al.

THE VALUE OF QUANTIFERON IN THE DIFFERENTIAL DIAGNOSIS OF CROHN'S DISEASE AND INTESTINAL TUBERCULOSIS
THE VALUE OF QUANTIFERON IN THE DIFFERENTIAL DIAGNOSIS OF CROHN'S DISEASE AND INTESTINAL TUBERCULOSIS

PP 05 IBD (Posters)  et al.

RECOMBINANT CALPROTECTIN AS A PROMISING TOOL TO HARMONIZE MRP-8/MRP-14 IMMUNOASSAYS
RECOMBINANT CALPROTECTIN AS A PROMISING TOOL TO HARMONIZE MRP-8/MRP-14 IMMUNOASSAYS

PP 05 IBD (Posters)  et al.

THE EFFECT OF COMMONLY PRESCRIBED MEDICATIONS ON THE TRANSCRIPTOME OF PATIENTS SUFFERING FROM IBD AND OTHER CHRONIC INFLAMMATORY DISEASES
THE EFFECT OF COMMONLY PRESCRIBED MEDICATIONS ON THE TRANSCRIPTOME OF PATIENTS SUFFERING FROM IBD AND OTHER CHRONIC INFLAMMATORY DISEASES

PP 05 IBD (Posters)  et al.

HYDROGEN GAS INHALATION IMPROVED INTESTINAL MICROBIOTA IN ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
HYDROGEN GAS INHALATION IMPROVED INTESTINAL MICROBIOTA IN ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

PP 05 IBD (Posters)  et al.

RISK FACTORS FOR INTESTINAL AND EXTRA-INTESTINAL CANCERS IN INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY
RISK FACTORS FOR INTESTINAL AND EXTRA-INTESTINAL CANCERS IN INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY

PP 05 IBD (Posters)  et al.

REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY
REAL-WORLD DATA IN INFLAMMATORY BOWEL DISEASES ON VEDOLIZUMAB THERAPY: INTERIM ANALYSIS OF THE NON-INTERVENTIONAL LISTEN II STUDY

PP 05 IBD (Posters)  et al.

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

PP 05 IBD (Posters)  et al.

THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE
THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

PREVALENCE OF GASTROINTESTINAL SYMPTOMS, QUALITY OF LIFE, VISCERAL HYPERSENSITIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION
PREVALENCE OF GASTROINTESTINAL SYMPTOMS, QUALITY OF LIFE, VISCERAL HYPERSENSITIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION

PP 05 IBD (Posters)  et al.

SYSTEMIC INFLAMMATORY PROTEIN PROFILES OF INFLAMMATORY BOWEL DISEASE PATIENTS - A PRELIMINARY STUDY
SYSTEMIC INFLAMMATORY PROTEIN PROFILES OF INFLAMMATORY BOWEL DISEASE PATIENTS - A PRELIMINARY STUDY

PP 05 IBD (Posters)  et al.

LONG TERM PERSISTENCE OF USTEKINUMAB IN CROHN’S DISEASE: CLINICAL OUTCOMES AND PROGNOSTIC FACTORS
LONG TERM PERSISTENCE OF USTEKINUMAB IN CROHN’S DISEASE: CLINICAL OUTCOMES AND PROGNOSTIC FACTORS

PP 05 IBD (Posters)  et al.

SYSTEMATIC REVIEW AND META-ANALYSIS: PSYCHOLOGICAL THERAPIES ARE ASSOCIATED WITH SHORT-TERM IMPROVEMENTS IN PSYCHOLOGICAL HEALTH IN INFLAMMATORY BOWEL DISEASE
SYSTEMATIC REVIEW AND META-ANALYSIS: PSYCHOLOGICAL THERAPIES ARE ASSOCIATED WITH SHORT-TERM IMPROVEMENTS IN PSYCHOLOGICAL HEALTH IN INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE
RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE

PP 05 IBD (Posters)  et al.

THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE
THE DEPENDENCE OF THE LEVEL OF GLYCOPROTEIN TYPE 2 ON THE LEVEL OF ZONULIN IN CROHN'S DISEASE

PP 05 IBD (Posters)  et al.

DISEASE OUTCOMES CAN BE PREDICTED BY MEMBERSHIP OF NOVEL SYMPTOM CLUSTERS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM A PROSPECTIVE LONGITUDINAL FOLLOW-UP STUDY
DISEASE OUTCOMES CAN BE PREDICTED BY MEMBERSHIP OF NOVEL SYMPTOM CLUSTERS IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM A PROSPECTIVE LONGITUDINAL FOLLOW-UP STUDY

PP 05 IBD (Posters)  et al.

BIOELECTRICAL IMPEDANCE ANALYSIS REVEALED DIFFERENCES BETWEEN LEAN AND NON-LEAN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CROHN’S DISEASE
BIOELECTRICAL IMPEDANCE ANALYSIS REVEALED DIFFERENCES BETWEEN LEAN AND NON-LEAN NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

VITAMIN DEFICIENCIES IN CROHN'S DISEASE
VITAMIN DEFICIENCIES IN CROHN'S DISEASE

PP 05 IBD (Posters)  et al.

RISK FACTORS OF MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
RISK FACTORS OF MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

PP 05 IBD (Posters)  et al.

Item 381 - 400 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
20
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42